首页|禾蔻安双基因甲基化检测在子宫内膜癌筛查中的应用价值

禾蔻安双基因甲基化检测在子宫内膜癌筛查中的应用价值

扫码查看
原文链接
  • 万方数据
  • 维普
目的 探讨禾蔻安双基因(CDO1和CELF4)甲基化检测在异常子宫出血患者中子宫内膜癌筛查的应用价值。方法 选取2021年7月—2022年6月因异常子宫出血就诊于甘肃省妇幼保健院宫腔镜门诊的患者216例，收集宫颈脱落细胞进行双基因甲基化检测，同时收集患者基本信息、肿瘤生物学标记物与子宫内膜厚度等。以宫腔镜下子宫内膜组织病理学诊断为金标准，分析禾蔻安双基因甲基化检测对异常子宫出血女性中子宫内膜癌检出的敏感性与特异性。结果 单因素分析中，年龄(P=0。001)、体重指数(BMI，P=0。002)、糖尿病(P=0。012)、绝经(P<0。001)、CDO1和CELF4甲基化(均P<0。001)对判断是否罹患子宫内膜癌的差异有统计学意义。二元Logistic回归分析结果显示，BMI的比值比(OR)为3。970(95%CI:[1。058，14。895]，P=0。041)，绝经的OR为18。702(95%CI:[1。847，189。370]，P=0。013)，CDO1、CELF4甲基化的OR分别为22。351(95%CI:[2。250，221。989]，P=0。008)、60。995(95%CI:[5。992，620。920]，P=0。001)。CDO1和CELF4甲基化检测敏感性为91。2%(95%CI:[76。3%，98。1%])、特异性为96。7%(95%CI:[93。0%，98。8%]);超声检查的敏感性、特异性分别为55。9%(95%CI:[37。9%，72。8%])和78。6%(95%CI:[71。9%，84。3%])。血清癌胚抗原 125检查的敏感性、特异性分别为 32。4%(95%CI:[17。4%，50。5%])和 76。4%(95%CI:[69。0%，82。8%])。结论 对于绝经后女性，禾蔻安双基因甲基化检测较目前妇科检查中的血清癌胚抗原125与超声检查具有更高的敏感性与特异性，可提示子宫内膜癌高风险。
Clinical value of CISENDO CDO1/CELF4 dual gene methy-lation detection in endometrial cancer screening for females with abnormal uterine bleeding
Objective To explore the application value of CISENDO dual gene methylation detection(CDO1 and CELF4)in endometrial cancer screening in women with abnormal uterine bleeding.Methods A total of 216 patients who presented with abnormal uterine bleeding at the Gansu Provincial Maternal and Child-care Hospital's hysteroscopy outpatient clinic between July 2021 and June 2022 were selected for this study.Cervical exfoliated cells were collected for dual-gene methylation testing,alongside the collection of basic patient information,tumor biological markers,and endometrial thickness assessed through ultrasound.Using the histopathological diagnosis of endometrial tissue obtained via hysteroscopy as the gold standard,the sensitivity and specificity of dual-gene methylation testing for detecting endometrial cancer in women with abnormal uterine bleeding were analysed.Results In univariate analysis,age(P=0.001),body mass index(P=0.002),diabetes(P=0.012),menopause(P<0.001),CDO1 methylation(P<0.001),and CELF4 methylation(P<0.001)have an impact on the risk of endometrial cancer,and the differences are statistically significant.Binary logistic regression analysis results showed that the odds ratio(OR)value of body mass index was 3.970(95%CI:[1.058,14.895]),P=0.041),the OR value of menopause was 18.702(95%CI:[1.847,189.370],P=0.013),The OR values of CDO1 methylation and CELF4 methylation were 22.351(95%CI:[2.250,221.989],P=0.008),60.995(95%CI:[5.992,620.920],P=0.001),respectively.CISENDO(CDO1 and CELF4)dual gene methylation detection has a sensitivity of 91.2%(95%CI:[76.3%,98.1%])and a specificity of 96.7%(95%CI:[93.0%,98.8%]);the sensitivity and specificity of ultrasound examination are 55.9%(95%CI:[37.9%,72.8%])and 78.6%(95%CI:[71.9%,84.3%]);the sensitivity and specificity of carbohydrate antigen 125 were 32.4%(95%CI:[17.4%,50.5%])and 76.4%(95%CI:[69.0%,82.8%]).Conclusion For postmenopausal women,dual-gene methylation testing demonstrates higher sensitivity and specificity compared to the currently utilized serum carbohydrate antigen 125 and ultrasound examinations,indicating a higher risk of endometrial cancer.

endometrial cancer screeningabnormal uterine bleedingdual gene methylationnon-invasive detection

蔡炳昕、李浏钰、刘博、刘沛、王林海、王义山、刘禹利、王紫芸、杜珺

展开 >

甘肃省妇幼保健院 妇一科,甘肃 兰州 730050

北京起源聚禾生物科技有限公司,北京 102600

广东药科大学附属第一医院 精准医学中心,广东 广州 510000

子宫内膜癌筛查 异常子宫出血 禾蔻安双基因甲基化 无创检测

兰州市科技局指导性计划资助项目甘肃省自然科学基金资助项目

2022-5-9223IRRA1380

2024

10.13885/j.issn.1000-2812.2024.07.004

兰州大学学报(医学版)
兰州大学

兰州大学学报(医学版)

CSTPCD
影响因子：0.641
ISSN：1000-2812
年,卷(期)：2024.50(7)